Cancer Research Blog

Bringing You the Latest in the Search For a Cure

Month: October 2015

Persistence of Genetic Mutations after Chemotherapy Linked to Poor Outcomes in Some Patients with AML

Patients with acute myeloid leukemia (AML) who achieved remission, but who had bone marrow cells that continued to exhibit leukemia-associated genetic mutations 1 month after the initiation of chemotherapy, had a substantially increased risk of relapse and reduced survival, according to a new study.

Published August 25 in the Journal of the American Medical Association (JAMA), the study showed that identifying the full set of leukemia-related mutations in AML cells at the time of diagnosis was no better at predicting disease relapse than current standard of care methods. However, the persistence of mutations after chemotherapy was associated with an increased risk of relapse and shorter survival.

NCI’s Steven Rosenberg Wins Service to America Medal

The Partnership for Public Service has awarded Steven A. Rosenberg, M.D., chief of the Surgery Branch in NCI’s Center for Cancer Research, with its highest 2015 Samuel J. Heyman Service to America Medal, or Sammie, for his research to develop life-saving immune-based therapies for patients with advanced cancers.

Dr. Rosenberg, a pioneer in cancer immunotherapy who has been conducting research at NCI for more than 40 years, was named the Federal Employee of the Year, the top Sammie medal awarded by the Partnership for Public Service. He will receive the award at a ceremony this evening in Washington, D.C.

Progress against Cancer: The Role of Basic Science

The following is the second in a series of posts from senior NCI scientists and leaders on NCI’s Annual Plan and Budget Proposal for Fiscal Year 2017, which was officially submitted to the President on September 17, 2015. The proposal provides an overview of NCI’s priorities and key initiatives and the institute’s funding request for the President to consider in formulating his own Fiscal Year (FY) 2017 budget proposal.

In this second post, Acting NCI Director Doug Lowy, M.D., discusses the critical contribution of basic science in fostering progress against cancer.

TCGA Wins 2015 Sammies People’s Choice Award

The Cancer Genome Atlas (TCGA), co-sponsored by NCI and the National Human Genome Research Institute (NHGRI), was honored with the People’s Choice Award at the 2015 Partnership for Public Service Sammies gala on October 7.

This is the first year for the People’s Choice Award, which was presented to Jean-Claude Zenklusen, Ph.D., director of NCI’s TCGA program office, and Carolyn Hutter, Ph.D., the NHGRI team lead for TCGA, who together represented the government staff and researchers who have worked on TCGA over the past decade.

FDA Approves Combination Drug for Patients with Advanced Colorectal Cancer

On September 22, the Food and Drug Administration (FDA) approved a tablet that combines the drugs trifluridine and tipiracil hydrochloride (Lonsurf®) to treat patients with metastatic colorectal cancer whose disease progressed after standard treatments. The drug combination was previously known as TAS-102.

The safety and efficacy of trifluridine and tipiracil was tested in a randomized phase III clinical trial of 800 primarily Japanese patients with metastatic colorectal cancer, the results of which were published earlier this year in the New England Journal of Medicine.

New on NCI’s Websites

NCI is constantly publishing new information on its websites, so periodically we’ll provide updates on new content of interest to the cancer community.

Children with Cancer: A Guide for Parents is a newly revised NCI publication that is intended to help parents cope with the challenges of caring for a child with cancer. This booklet provides practical information about finding doctors and hospitals, talking with your child about the disease, locating sources of support, and keeping medical information organized. 

Long-Term Study Finds No Increased Risk of Miscarriage after HPV Vaccination

Women in a clinical trial who became pregnant after vaccination with a human papillomavirus (HPV) vaccine did not have an increased risk of miscarriage compared with women who were not exposed to the vaccine, according to a new analysis of additional data from a clinical trial conducted in Costa Rica.

The observational study, led by researchers in Costa Rica and from the National Cancer Institute, appeared September 7 in the British Medical Journal.

Bringing Cancer Research to the Public: NCI’s Networks and Programs

The following is the third in a series of posts from senior NCI scientists and leaders on NCI’s Annual Plan and Budget Proposal for Fiscal Year 2017, which was submitted to the President on September 17, 2015. The proposal provides an overview of NCI’s priorities and key initiatives and the institute’s funding request for the President to consider in formulating his own Fiscal Year (FY) 2017 budget proposal.

In this third post, Warren Kibbe, Ph.D., director of the NCI Center for Biomedical Informatics and Information Technology, and Jeff Abrams, M.D., acting director for clinical research in NCI’s Division of Cancer Treatment and Diagnosis, discuss NCI’s role in leading the National Cancer Program.

Cancer Research Blog © 2016
Contact: jim@jdgblogs.com
Frontier Theme
yes